Pharmaceuticals - Community Register


Community register of medicinal products for human use


Product information

Invented name: Vimizim   
Auth. number : EU/1/14/914
INN : elosulfase alfa
Orphan status based on designation EU/3/09/657 added on 30/04/2014
ATC: Anatomical main group: A - Alimentary tract and metabolism
Therapeutic subgroup: A16 - Other alimentary tract and metabolism products
Pharmacological subgroup: A16A - Other alimentary tract and metabolism products
Chemical subgroup: A16AB - Enzymes
Chemical substance: A16AB12 - Elosulfase alfa
(See WHO ATC Index)
Indication: Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.
Marketing Authorisation Holder: BioMarin Europe Ltd
164 Shaftesbury Avenue, London WC2H 8HL, United Kingdom

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/04/2014 Centralised - Authorisation EMEA/H/C/2779 (2014)2921 of 28/04/2014